Business Context and Reporting Period
This Form 8-K is a current report filed by Skye Bioscience, Inc. (Skye) on March 17, 2026. The filing addresses a regulatory notice received from the Nasdaq Listing Qualifications Department regarding the Company's compliance with continued listing standards on The Nasdaq Global Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the stock price performance: the closing bid price for Skye's Common Stock has been below the minimum $1.00 per share requirement for the last 30 consecutive business days.
Material Changes
The material event reported is the receipt of a deficiency letter from Nasdaq citing a failure to satisfy the minimum bid price requirement under Rule 5450(a)(1). This deficiency has no immediate effect on the listing, and the stock continues to trade under the symbol "SKYE."
Outlook, Risks, and Contingencies
- Compliance Timeline: Skye has been granted 180 calendar days, until September 14, 2026, to regain compliance.
- Remediation Options: The Company may regain compliance if the bid price closes at $1.00 or more for 10 consecutive business days before the deadline. Alternatively, the Company may implement a reverse stock split, which must be completed no later than ten business days prior to September 14, 2026.
- Secondary Compliance Period: If compliance is not achieved by September 14, 2026, the Company may be afforded a second 180-day period, contingent upon meeting market value of publicly held shares and other initial listing standards for The Nasdaq Capital Market.
- Risks: Management states there can be no assurance that the Company will be able to regain compliance with Rule 5450(a)(1) or other Nasdaq Listing Rules.
Investor Verification Checklist
- Verify the current closing bid price of SKYE stock to assess the gap from the $1.00 threshold.
- Monitor for any announcements regarding a potential reverse stock split before the September 14, 2026 deadline.
- Review the Company's market value of publicly held shares to determine eligibility for a second compliance period if the initial deadline is missed.
- Check for subsequent filings that may update the status of the deficiency or confirm compliance.